Recent News Releases

 

Latest News Releases

Latest News Releases

CSL Continues to Advance R&D Capabilities
04 Dec 2019 Company

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.

Paul Perreault Named Among Best Performing CEOs
23 Oct 2019 Company

Harvard Business Review (HBR) named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for 2019.

Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings

CSL Media Statement
18 Oct 2019

CSL statement in response to media reports on case against Joseph Chiao

CSL Limited Celebrates 25 Years on the ASX
14 Oct 2019 Company

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

$2.5 million CSL Centenary Fellowships announced
10 Oct 2019 Company

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

CSL to Move Global Headquarters
07 Aug 2019 Company

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

Want to know more about how CSL, and our CSL Behring division are sharing stories of biotech's promise?

Visit Vita
News archive 2016 pdf
News archive 2015 pdf
News archive 2014 pdf
News archive 2013 pdf

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter